<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35303907</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD.</ArticleTitle><Pagination><StartPage>22</StartPage><MedlinePgn>22</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00525-z</ELocationID><Abstract><AbstractText>Neuroinflammation is an important hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). An inflammatory reaction to neuronal injury is deemed vital for neuronal health and homeostasis. However, a continued activation of the inflammatory response can be detrimental to remaining neurons and aggravate the disease process. Apart from a disease modifying role, some evidence suggests that neuroinflammation may also contribute to the upstream cause of the disease. In this review, we will first focus on the role of neuroinflammation in the pathogenesis of chromosome 9 open reading frame 72 gene (C9orf72) hexanucleotide repeat expansions (HRE)-mediated ALS/FTD (C9-ALS/FTD). Additionally, we will discuss evidence from ex vivo and in vivo studies and finally, we briefly summarize the trials and progress of anti-inflammatory therapies.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8247-1866</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Experimental Neurology, Center for Brain and Disease Research, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, 602, 3000, Leuven, PB, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Antwerp, 2650, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Beckers</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Experimental Neurology, Center for Brain and Disease Research, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, 602, 3000, Leuven, PB, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gossye</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Antwerp, 2650, Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Center for Molecular Neurology, Neurodegenerative Brain Diseases, University of Antwerp, 2000, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, 2000, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium. philip.vandamme@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Experimental Neurology, Center for Brain and Disease Research, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, 602, 3000, Leuven, PB, Belgium. philip.vandamme@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium. philip.vandamme@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-inflammatory therapies</Keyword><Keyword MajorTopicYN="N">Astrocytes</Keyword><Keyword MajorTopicYN="N">C9orf72 HRE-mediated ALS/FTD</Keyword><Keyword MajorTopicYN="N">In-vivo and ex-vivo models</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Peripheral immune cells</Keyword></KeywordList><CoiStatement>The authors declare to have no conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35303907</ArticleId><ArticleId IdType="pmc">PMC8932121</ArticleId><ArticleId IdType="doi">10.1186/s13024-022-00525-z</ArticleId><ArticleId IdType="pii">10.1186/s13024-022-00525-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59(7):1077&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IRA. Review: Neuropathology of non-tau frontotemporal lobar degeneration. Neuropathology and applied neurobiology. 2019;45(1):19&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015;33(4):855&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;5(3):17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018;93(11):1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, et al. Typical and Atypical Pathology in Primary Progressive Aphasia Variants. Ann Neurol. 2017;81(3):430&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5421819</ArticleId><ArticleId IdType="pubmed">28133816</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain : a journal of neurology. 2011;134(Pt 9):2582&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Delgadillo D, Piquard A, Bruneteau G, Pradat P-F, Salachas F, et al. The range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performance. Amyotroph Lateral Scler. 2011;12(5):372&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">21585273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65(4):586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. The Lancet Neurology. 2012;11(1):54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129(2):154&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814458</ArticleId><ArticleId IdType="pubmed">20561356</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chi&#xf2; A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7(1):2116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L, Van Schoor E, Ospitalieri S, Ronisz A, Weishaupt JH, Otto M, et al. Dipeptide repeat protein and TDP-43 pathology along the hypothalamic-pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathol. 2020;140(5):777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">32862270</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, et al. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurol. 2017;74(4):445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">28192553</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12(10):978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F, et al. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging. 2019;74:234.e1&#x2013;234.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30337192</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boill&#xe9;e S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet. 2012;49(4):258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaivola K, Salmi SJ, Jansson L, Launes J, Hokkanen L, Niemi A-K, et al. Carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is a risk factor for ALS in the Finnish population. Acta Neuropathol Commun. 2020;8(1):187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654028</ArticleId><ArticleId IdType="pubmed">33168078</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12(10):978&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, et al. Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging. 2015;36(1):546.e1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270445</ArticleId><ArticleId IdType="pubmed">25179228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JL, Finch NA, Baker MC, Kachergus JM, DeJesus-Hernandez M, Pereira K, et al. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener. 2020;15(1):7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="pubmed">32000838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24(11):3133&#x2013;3142.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O. Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):148&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">24053774</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Gallego J, Guerrero-L&#xf3;pez R, Marcos A, Gil-Neciga E, Sainz MJ, et al. C9ORF72 hexanucleotide expansions of 20&#x2013;22 repeats are associated with frontotemporal deterioration. Neurology. 2013;80(4):366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">23284068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24(11):3133&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, Fabros M, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123(3):409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322555</ArticleId><ArticleId IdType="pubmed">22228244</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135(Pt 3):723&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Gr&#xe4;sser FA, Gijselinck I, May S, Rentzsch K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126(6):881&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, et al. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol. 2017;134(2):255&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110(51):E4968&#x2013;4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126(6):845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Rothstein JD. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci. 2016;17(6):383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, Ramic M, Esanov R, Liu W, Rybin MJ, Gaidosh G, et al. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol Neurodegener. 2020;15(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin W-L, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang Y-J, Jansen-West K, Ash PEA, Caulfield T, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126(6):829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Nana AL, Yokoyama JS, Seeley WW. C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol. 2019;137(1):1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546170</ArticleId><ArticleId IdType="pubmed">30368547</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen H-J, Shaw CE. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12(2):352&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, Gendron TF, Jansen-West K, Del Rosso G, Yue M, Jiang P, Gomes E, Tong J, Daughrity LM, Avendano NM, Castanedes-Casey M, Shao W, Oskarsson B, Tomassy GS, McCampbell A, Rigo F, Dickson DW, Shorter J, Zhang YJ, Petrucelli L. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12(559):eabb3774. 10.1126/scitranslmed.abb3774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Weintraub S, Rademakers R, Baker M, Ahmadian SS, Rademaker A, et al. Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. Neuropathology. 2013;33(2):122&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3449045</ArticleId><ArticleId IdType="pubmed">22702520</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Bury JJ, Heath PR, Wyles M, Higginbottom A, Gelsthorpe C, et al. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. PLoS One. 2015;10(5):e0127376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4446097</ArticleId><ArticleId IdType="pubmed">26016851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VMY, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119(4):409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta neuropathologica. 2012;124(3):353&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422616</ArticleId><ArticleId IdType="pubmed">22890575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111(12):E1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122(6):673&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Disease Mechanisms of C9ORF72 Repeat Expansions. Cold Spring Harb Perspect Med. 2018;8(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880161</ArticleId><ArticleId IdType="pubmed">28130314</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng C-Y, Tahraoui-Bories J, Martinat C, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun. 2018;6(1):72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, MacNair L, McGoldrick P, McKeever PM, McLean JR, Zhang M, et al. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann Neurol. 2015;78(4):568&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers J, Tharkeshwar AK, Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021;26:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632097</ArticleId><ArticleId IdType="pubmed">33632058</ArticleId></ArticleIdList></Reference><Reference><Citation>Braems E, Swinnen B, Van Den Bosch L. C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD? Acta Neuropathologica [Internet]. 2020. Available from: 10.1007/s00401-020-02214-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547039</ArticleId><ArticleId IdType="pubmed">32876811</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A, et al. C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv. 2021;7(15).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034861</ArticleId><ArticleId IdType="pubmed">33837088</ArticleId></ArticleIdList></Reference><Reference><Citation>Laflamme C, McKeever PM, Kumar R, Schwartz J, Kolahdouzan M, Chen CX, et al. Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. Elife. 2019;15:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794092</ArticleId><ArticleId IdType="pubmed">31612854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang W-H, Hung S-T, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W, Van Den Bosch L. RNA toxicity in non-coding repeat expansion disorders. EMBO J. 2020;39(1):e101112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939197</ArticleId><ArticleId IdType="pubmed">31721251</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Walsh MJ, Higginbottom A, Robin Highley J, Dickman MJ, Edbauer D, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 2014;137(Pt 7):2040&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, et al. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol. 2017;134(2):255&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, Rohrer J, Polke J, Beck J, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta neuropathologica [Internet]. 2013;126. Available from: https://link.springer.com/content/pdf/10.1007/s00401-013-1147-0.pdf</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EAJ, Shaw PG, Kim M-S, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Geng Y, Liu C, Miao H, Ren Y, Xu N, et al. Characterizations of distinct parallel and antiparallel G-quadruplexes formed by two-repeat ALS and FTD related GGGGCC sequence. Sci Rep. 2018;8(1):2366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799222</ArticleId><ArticleId IdType="pubmed">29402965</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SYR, Macgregor RBJ, Pearson CE. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem. 2013;288(14):9860&#x2013;9866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatovec S, Kovanda A, Rogelj B. Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiol Aging. 2014;35(10):2421.e1&#x2013;2421.e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24836899</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C, Herranz-Martin S, Karyka E, Liao C, Lewis K, Elsayed W, et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat Neurosci. 2017;20(9):1225&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Cleary JD, Ranum LPW. Repeat-Associated Non-ATG Translation: Molecular Mechanisms and Contribution to Neurological Disease. Annu Rev Neurosci. 2019;8(42):227&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687071</ArticleId><ArticleId IdType="pubmed">30909783</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz A, Pinheiro Marques J, Oertig I, Maharjan N, Saxena S. Emerging Perspectives on Dipeptide Repeat Proteins in C9ORF72 ALS/FTD. Front Cell Neurosci. 2021;15:637548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930069</ArticleId><ArticleId IdType="pubmed">33679328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, et al. Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell. 2016;167(3):789&#x2013;802.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>White MK, Johnson EM, Khalili K. Multiple roles for Puralpha in cellular and viral regulation. Cell Cycle. 2009;8(3):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683411</ArticleId><ArticleId IdType="pubmed">19182532</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Mol Cell. 2017;65(6):1044&#x2013;1055.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167(3):774&#x2013;788.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum Mol Genet. 2015;24(9):2426&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron. 2017;96(2):285&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Grima JC, Rothstein JD, Lloyd TE. Nucleocytoplasmic transport in C9orf72-mediated ALS/FTD. Nucleus. 2016;7(2):132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4916865</ArticleId><ArticleId IdType="pubmed">27116041</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173(4):958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S, Lopez-Gonzalez R, Kunz RC, Gangopadhyay J, Borufka C, Gygi SP, et al. Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients. Cell Rep. 2017;19(11):2244&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="pubmed">28614712</ArticleId></ArticleIdList></Reference><Reference><Citation>Abo-Rady M, Kalmbach N, Pal A, Schludi C, Janosch A, Richter T, et al. Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins. Stem Cell Reports. 2020;14(3):390&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066330</ArticleId><ArticleId IdType="pubmed">32084385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, et al. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92(2):383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoreschi K, Laurence A, O&#x2019;Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782696</ArticleId><ArticleId IdType="pubmed">19290934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1&#x2013;2):1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12039028</ArticleId></ArticleIdList></Reference><Reference><Citation>Liongue C, O&#x2019;Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS One. 2012;7(3):e32777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296744</ArticleId><ArticleId IdType="pubmed">22412924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem. 2008;107(1):50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18636982</ArticleId></ArticleIdList></Reference><Reference><Citation>Molet J, Mauborgne A, Diallo M, Armand V, Geny D, Villanueva L, et al. Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics. J Neurochem. 2016;136(1):133&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">26440453</ArticleId></ArticleIdList></Reference><Reference><Citation>Przanowski P, Dabrowski M, Ellert-Miklaszewska A, Kloss M, Mieczkowski J, Kaza B, et al. The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J Mol Med (Berl) 2014;92(3):239&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3940857</ArticleId><ArticleId IdType="pubmed">24097101</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med. 2006;12(7):829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783372</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Hall CE, Sibley CR, Cymes T, Forostyak S, Carlino G, et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nat Commun. 2017;8(1):1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660125</ArticleId><ArticleId IdType="pubmed">29079839</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA, Burda JE, Ren Y, Ao Y, O&#x2019;Shea TM, Kawaguchi R, et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature. 2016;532(7598):195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Involvement of p38 MAPK in Synaptic Function and Dysfunction. Int J Mol Sci. 2020;21(16).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460549</ArticleId><ArticleId IdType="pubmed">32781522</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhong W, Zhang M, Zhang R, Hu W. P38 Mitogen-activated Protein Kinase and Parkinson&#x2019;s Disease. Transl Neurosci. 2018;9:147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234472</ArticleId><ArticleId IdType="pubmed">30473884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Nan G. The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a Discovery Target in Stroke. J Mol Neurosci. 2016;59(1):90&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26842916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Lee H, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer&#x2019;s disease. Neurosignals. 2002;11(5):270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566928</ArticleId></ArticleIdList></Reference><Reference><Citation>Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med. 2000;28(4 Suppl):N67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807318</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Hara H, N&#xfa;&#xf1;ez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 2016;41(12):1012&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123939</ArticleId><ArticleId IdType="pubmed">27669650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Shi L, Wang Y, Chen S, Zhang J. Recent Advances of the NLRP3 Inflammasome in Central Nervous System Disorders. J Immunol Res. 2016;2016:9238290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019917</ArticleId><ArticleId IdType="pubmed">27652274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7807242</ArticleId><ArticleId IdType="pubmed">31036962</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratwicke J, Jahanshahi M, Foltynie T. Parkinson&#x2019;s disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454&#x2013;1476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4614131</ArticleId><ArticleId IdType="pubmed">25888551</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14(4):388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):459&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Bao Cutrona M, Cheroni C, Grignaschi G, Lo Coco D, Peviani M, et al. Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase. Neurodegener Dis. 2005;2(3&#x2013;4):128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909017</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, Simpson EP, Kim SH, Pan T, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Neusch C, B&#xe4;hr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve. 2007;35(6):712&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">17373702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51(4):241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15846792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine Y, Takeda K, Ichijo H. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med. 2006;6(1):87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyck L, Santamaria ID, Pakkenberg B, Chemnitz J, Schr&#xf8;der HD, Finsen B, et al. An empirical analysis of the precision of estimating the numbers of neurons and glia in human neocortex using a fractionator-design with sub-sampling. J Neurosci Methods. 2009;182(2):143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">19520115</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging. 2008;29(11):1754&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">17544173</ArticleId></ArticleIdList></Reference><Reference><Citation>Baufeld C, O&#x2019;Loughlin E, Calcagno N, Madore C, Butovsky O. Differential contribution of microglia and monocytes in neurodegenerative diseases. J Neural Transm (Vienna) 2018;125(5):809&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255107</ArticleId><ArticleId IdType="pubmed">29063348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16(12):1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39(1):151&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">2089275</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143(12):3526&#x2013;3539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50(1):30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017;46(6):957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:480739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753746</ArticleId><ArticleId IdType="pubmed">23997430</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D&#x2019;Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front Aging Neurosci. 2017;9:242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12(2):364&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nature reviews Neurology. 2017;13(7):406&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28621768</ArticleId></ArticleIdList></Reference><Reference><Citation>Robelin L, Gonzalez De Aguilar JL. Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? Biomed Res Int. 2014;2014:525097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060749</ArticleId><ArticleId IdType="pubmed">24991560</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 2012;26(8):3103&#x2013;3117.</Citation><ArticleIdList><ArticleId IdType="pubmed">22516295</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O, Prinz M. Microglia Heterogeneity in the Single-Cell Era. Cell Rep. 2020;30(5):1271&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">32023447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19(8):987&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch U-K. Functional diversity of microglia - how heterogeneous are they to begin with? Front Cell Neurosci. 2013;7:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653062</ArticleId><ArticleId IdType="pubmed">23717262</ArticleId></ArticleIdList></Reference><Reference><Citation>Speicher AM, Wiendl H, Meuth SG, Pawlowski M. Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration. Mol Neurodegener. 2019;14(1):46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921408</ArticleId><ArticleId IdType="pubmed">31856864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzini I, Alsop E, Levy J, Gittings LM, Rabichow BE, Lall D, et al. Activated iPSC-microglia from C9orf72 ALS/FTD patients exhibit endosomal-lysosomal dysfunction. bioRxiv. 202;2020.09.03.277459.</Citation></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351(6279):1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostalski H, Leskel&#xe4; S, Huber N, Katisko K, Cajanus A, Solje E, et al. Astrocytes and Microglia as Potential Contributors to the Pathogenesis of C9orf72 Repeat Expansion-Associated FTLD and ALS. Front Neurosci. 2019;13:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529740</ArticleId><ArticleId IdType="pubmed">31156371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Thonhoff JR, Thome AD, Faridar A, Wang J, et al. Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls. iScience. 2020;23(6):101192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286967</ArticleId><ArticleId IdType="pubmed">32521508</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee H-C, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;16(6):23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang J-Y, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudria-Lopez E, Koppers M, de Wit M, van der Meer C, Westeneng H-J, Zundel CAC, et al. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathol. 2016;132(1):145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911370</ArticleId><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, et al. TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z, Liu L, Tao Z, Wang R, Ren H, Sun H, et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat Commun. 2019;10(1):2906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351(6279):1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol. 2017;134(2):241&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Burberry A, Wang J-Y, Sandoe J, Ghosh S, Udeshi ND, et al. The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. Genes Dev. 2018;32(13&#x2013;14):929&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075033</ArticleId><ArticleId IdType="pubmed">29950492</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine W, Sun L, Wang K-W, Liu A, Jain R, San Miguel M, et al. Excessive endosomal TLR signaling causes inflammatory disease in mice with defective SMCR8-WDR41-C9ORF72 complex function. Proc Natl Acad Sci U S A. 2018;115(49):E11523&#x2013;E11531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298088</ArticleId><ArticleId IdType="pubmed">30442666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang Y-J, Castanedes-Casey M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348(6239):1151&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener. 2019;14(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair KD, Zhou Q, Michaelsen M, Wefers B, Brill MS, Janjic A, et al. Congenic expression of poly-GA but not poly-PR in mice triggers selective neuron loss and interferon responses found in C9orf72 ALS. Acta Neuropathol. 2020;140(2):121&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360660</ArticleId><ArticleId IdType="pubmed">32562018</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;langer M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14(6):724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">22152301</ArticleId></ArticleIdList></Reference><Reference><Citation>Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron. 2014;81(2):229&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984950</ArticleId><ArticleId IdType="pubmed">24462092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron. 1999;23(2):297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399936</ArticleId></ArticleIdList></Reference><Reference><Citation>Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB. Review: Astrocytes in Alzheimer&#x2019;s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol. 2017;43(4):281&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">27442752</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddleston M, Mucke L. Molecular profile of reactive astrocytes&#x2013;implications for their role in neurologic disease. Neuroscience. 1993;54(1):15&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130906</ArticleId><ArticleId IdType="pubmed">8515840</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007;28(3):138&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17276138</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha MK, Jo M, Kim J-H, Suk K. Microglia-Astrocyte Crosstalk: An Intimate Molecular Conversation. Neuroscientist. 2019;25(3):227&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">29931997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziff OJ, Clarke BE, Taha DM, Crerar H, Luscombe NM, Patani R. Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states. Genome Res. 2021;32(1):71&#x2013;84. 10.1101/gr.275939.121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8744676</ArticleId><ArticleId IdType="pubmed">34963663</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C, Galea E, Lakatos A, O&#x2019;Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24(3):312&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Madill M, McDonagh K, Ma J, Vajda A, McLoughlin P, O&#x2019;Brien T, et al. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain. 2017;10(1):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470320</ArticleId><ArticleId IdType="pubmed">28610619</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, Renusch S, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A. 2014;111(2):829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A, Myszczynska MA, Castelli LM, O&#x2019;Neill B, Kim Y, Talbot J, et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani P, Gagliardi S, Cova E, Cereda C. SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS. Neurol Res Int. 2011;2011:458427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096450</ArticleId><ArticleId IdType="pubmed">21603028</ArticleId></ArticleIdList></Reference><Reference><Citation>Fomin V, Richard P, Hoque M, Li C, Gu Z, Fissore-O&#x2019;Leary M, et al. The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling. Mol Cell Biol. 2018;38(22).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206455</ArticleId><ArticleId IdType="pubmed">30150298</ArticleId></ArticleIdList></Reference><Reference><Citation>Almad AA, Doreswamy A, Gross SK, Richard J-P, Huo Y, Haughey N, et al. Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016;64(7):1154&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635605</ArticleId><ArticleId IdType="pubmed">27083773</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A, Ben-Dor I, Ottolenghi M, Turetsky T, Gil Y, Sweetat S, et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, Siller R, et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013;110(12):4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Devlin A-C, Chouhan AK, Selvaraj BT, Stavrou M, Burr K, et al. Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology. Glia. 2020;68(5):1046&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078830</ArticleId><ArticleId IdType="pubmed">31841614</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian K, Huang H, Peterson A, Hu B, Maragakis NJ, Ming G-L, et al. Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo. Stem Cell Reports. 2017;8(4):843&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390239</ArticleId><ArticleId IdType="pubmed">28366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345(6201):1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014;111(11):E1035&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018;14(12):1640&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pubmed">30120040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol. 2008;214(2):161&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724989</ArticleId><ArticleId IdType="pubmed">18161744</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LLY, Cheung BKW, Li JCB, Lau ASY. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol. 2010;88(2):303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">20356901</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944738</ArticleId><ArticleId IdType="pubmed">24669294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Hadlock KG, Do H, Yu S, Honrada R, Champion S, et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2011;230(1&#x2013;2):114&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448551</ArticleId><ArticleId IdType="pubmed">20884065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74(6):677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, M&#xfc;ller K, Khalaji S, Bliederh&#xe4;user C, Ruf WP, Grozdanov V, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132(3):391&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res. 2007;29(8):772&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">17672928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2005;159(1&#x2013;2):215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Zhao W, Thonhoff JR, Wang J, Wen S, Appel SH. Increased activation ability of monocytes from ALS patients. Exp Neurol. 2020;328:113259.</Citation><ArticleIdList><ArticleId IdType="pubmed">32105709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A. 2009;106(49):20960&#x2013;20965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791631</ArticleId><ArticleId IdType="pubmed">19933335</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber DJ, Hickey WF, Harris BT. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation. 2010;28(7):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825214</ArticleId><ArticleId IdType="pubmed">20109233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano O, Beers DR, Henkel JS, Appel SH. Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology. 2012;78(11):833&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3304948</ArticleId><ArticleId IdType="pubmed">22377817</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S, Pays L. Gene co-expression analysis unravels a link between C9orf72 and RNA metabolism in myeloid cells. Acta Neuropathol Commun. 2015;15(3):64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608290</ArticleId><ArticleId IdType="pubmed">26472214</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Blauwendraat C, Heetveld S, Lynes EM, Castillo-Lizardo M, Dhingra A, et al. C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathol Commun. 2016;4(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832459</ArticleId><ArticleId IdType="pubmed">27079381</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Ron-Harel N, Gal H, Deczkowska A, Shifrut E, Ndifon W, et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc Natl Acad Sci U S A. 2013;110(6):2264&#x2013;2269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568380</ArticleId><ArticleId IdType="pubmed">23335631</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin I, Kipnis J. Learning and memory &#x2026; and the immune system. Learn Mem. 2013;20(10):601&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768198</ArticleId><ArticleId IdType="pubmed">24051097</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416069</ArticleId><ArticleId IdType="pubmed">25458968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64(1):110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8(6):289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">20559327</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ETA, Goodarzi H, Liao JT, O&#x2019;Keeffe S, Phatnani HP, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4(2):385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008;105(46):17913&#x2013;17918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A. 2008;105(40):15558&#x2013;15563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, de Vito G, Cecchi R, Riva N, Dina G, et al. Immune response in peripheral axons delays disease progression in SOD1(G93A) mice. J Neuroinflammation. 2016;13(1):261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Feng W, Huang R, Guo X, Chen Y, Zheng Z, et al. Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J Neurol Sci. 2014;347(1&#x2013;2):90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25312013</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol. 2006;24:257&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551250</ArticleId></ArticleIdList></Reference><Reference><Citation>Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128(1):7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747134</ArticleId><ArticleId IdType="pubmed">19689731</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi F-D, Ljunggren H-G, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol. 2011;11(10):658&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620656</ArticleId><ArticleId IdType="pubmed">21941294</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Shi F-D, Jung S, Pien GC, Wang J, Salazar-Mather TP, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006;20(7):896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675847</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74(12):1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. Nat Commun. 2020;11(1):1773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertwig L, Hamann I, Romero-Suarez S, Millward JM, Pietrek R, Chanvillard C, et al. CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. Eur J Immunol. 2016;46(8):1984&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5020316</ArticleId><ArticleId IdType="pubmed">27325505</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante-Duarte C, Weber A, Kr&#xe4;tzschmar J, Prozorovski T, Pikol S, Hamann I, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 2005;19(13):1902&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144955</ArticleId></ArticleIdList></Reference><Reference><Citation>Masera RG, Prolo P, Sartori ML, Staurenghi A, Griot G, Ravizza L, et al. Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer&#x2019;s disease. Psychoneuroendocrinology. 2002;27(4):447&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">11911998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Ingre C, Yin L, Li X, Andersson J, Seitz C, et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis: a longitudinal cohort study. medRxiv. 2021;10(05):21264570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923665</ArticleId><ArticleId IdType="pubmed">35287794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablasser A, Chen ZJ. cGAS in action: Expanding roles in immunity and inflammation. Science. 2019;363(6431).</Citation><ArticleIdList><ArticleId IdType="pubmed">30846571</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W. STING-Induced Inflammation - A Novel Therapeutic Target in ALS? N Engl J Med. 2021;384(8):765&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">33626258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulen MF, Koch U, Haag SM, Schuler F, Apetoh L, Villunger A, et al. Signalling strength determines proapoptotic functions of STING. Nat Commun. 2017;8(1):427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585373</ArticleId><ArticleId IdType="pubmed">28874664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan J, Liu BC, Muendlein HI, Weindel CG, Smirnova I, Tang AY, et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 2019;26(2):332&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329789</ArticleId><ArticleId IdType="pubmed">29786074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui X, Yang H, Li T, Tan X, Shi P, Li M, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019;567(7747):262&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">30842662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183(3):636&#x2013;649.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Woodruff TM. TDP-43 Puts the STING in ALS. Trends Neurosci. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33353765</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O&#x2019;Rourke JG, Y&#xe1;&#xf1;ez A, Markman JL, Ho R, Wang X, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Boziki MK, Kesidou E, Theotokis P, Mentis A-FA, Karafoulidou E, Melnikov M, et al. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020;10(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226078</ArticleId><ArticleId IdType="pubmed">32295236</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;uc M, Misiak B, Paw&#x142;owski M, Sta&#x144;czykiewicz B, Zab&#x142;ocka A, Szcze&#x15b;niak D, et al. Gut microbiota in dementia. critical review of novel findings and their potential application. Prog Neuropsychopharmacol Biol Psychiatry. 2021;10(104):110039.</Citation><ArticleIdList><ArticleId IdType="pubmed">32687964</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddy SL, Giovannelli I, Sassani M, Cooper-Knock J, Snyder MP, Segal E, et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS) BMC Med. 2021;19(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816375</ArticleId><ArticleId IdType="pubmed">33468103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing. Front Microbiol. 2016;7:1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028383</ArticleId><ArticleId IdType="pubmed">27703453</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol Rep. 2017;5(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617930</ArticleId><ArticleId IdType="pubmed">28947596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q, Shen J, Chen K, Zhou J, Liao Q, Lu K, et al. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci Rep. 2020;10(1):12998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398913</ArticleId><ArticleId IdType="pubmed">32747678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Restuadi R, McCrae AF, Van Eijk RP, Garton F, Henderson RD, et al. Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):549&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">32643435</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, et al. The fecal microbiome of ALS patients. Neurobiol Aging. 2018;61:132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">29065369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai C-D, Zheng J-J, An B-C, Huang H-F, Tan Z-C. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chin Med J (Engl) 2019;132(15):1815&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759115</ArticleId><ArticleId IdType="pubmed">31306225</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gioia D, Bozzi Cionci N, Baffoni L, Amoruso A, Pane M, Mogna L, et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC Med. 2020;18(1):153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298784</ArticleId><ArticleId IdType="pubmed">32546239</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature. 2020;582(7810):89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;&#xe4;skel&#xe4;inen O, Solje E, Hall A, Katisko K, Korhonen V, Tiainen M, et al. Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. J Alzheimers Dis. 2019;72(1):127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839456</ArticleId><ArticleId IdType="pubmed">31561355</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2020 Dec 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK326741/</Citation></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss&#xf9; P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, et al. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation. 2011;6(8):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141503</ArticleId><ArticleId IdType="pubmed">21645364</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Nicholas JM, Heller C, Foiani MS, Moore KM, Russell LL, et al. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Dement Geriatr Cogn Disord. 2020;49(1):56&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7513620</ArticleId><ArticleId IdType="pubmed">32344399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1-2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinilla G, Kumar A, Floaters MK, Pardo CA, Rothstein J, Ilieva H. Increased synthesis of pro-inflammatory cytokines in C9ORF72 patients. Amyotroph Lateral Scler Frontotemporal Degener. 2021;30:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33929933</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, Al Shweiki MR, Weishaupt JH, Landwehrmeyer GB, et al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with &lt;em&gt;C9orf72&lt;/em&gt; hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91(5):503.</Citation><ArticleIdList><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937795</ArticleId><ArticleId IdType="pubmed">31892365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutma E, Ceyz&#xe9;riat K, Amor S, Tsartsalis S, Millet P, Owen DR, et al. Cellular sources of TSPO expression in healthy and diseased brain. Eur J Nucl Med Mol Imaging. 2021;49(1):146&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712293</ArticleId><ArticleId IdType="pubmed">33433698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosenza-Nashat M, Zhao M-L, Suh H-S, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35(3):306&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693902</ArticleId><ArticleId IdType="pubmed">19077109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrova-Shumkovska J, Krstanoski L, Veenman L. Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update. Cells. 2020;9(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226777</ArticleId><ArticleId IdType="pubmed">32252470</ArticleId></ArticleIdList></Reference><Reference><Citation>Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19(5):24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30941587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauveau F, Boutin H, Van Camp N, Doll&#xe9; F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">18828015</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilarte TR. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Pharmacol Ther. 2019;194:44&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348013</ArticleId><ArticleId IdType="pubmed">30189290</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Z&#xfc;rcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia D, et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87(24):2554&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207001</ArticleId><ArticleId IdType="pubmed">27837005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Z&#xfc;rcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, et al. Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83(6):1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratai E-M, Alshikho MJ, Z&#xfc;rcher NR, Loggia ML, Cebulla CL, Cernasov P, et al. Integrated imaging of [(11)C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy (1)H-MRS in amyotrophic lateral sclerosis. Neuroimage Clin. 2018;20:357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092554</ArticleId><ArticleId IdType="pubmed">30112276</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Babu S, De Vocht J, Z&#xfc;rcher NR, Chew S, Tseng C-EJ, et al. Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. J Nucl Med. 2020;61(11):1621&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32169920</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Van Schoor E, De Vocht J, Koole M, Attili B, Celen S, et al. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. J Nucl Med. 2020;61(4):604&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198372</ArticleId><ArticleId IdType="pubmed">31562223</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Cope TE, Jones PS, Kaalund SS, Passamonti L, Allinson K, et al. Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain. 2020;143(3):1010&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089669</ArticleId><ArticleId IdType="pubmed">32179883</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">15562429</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Toomey CE, Strand C, Courtney R, Benson BC, Rohrer JD, et al. Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration. J Neuroinflammation. 2020;17(1):234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418403</ArticleId><ArticleId IdType="pubmed">32778130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N, Roemer SF, Bieniek KF, Murray ME, Baker MC, Kasanuki K, et al. Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Ann Clin Transl Neurol. 2019;6(9):1782&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764493</ArticleId><ArticleId IdType="pubmed">31448566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lant SB, Robinson AC, Thompson JC, Rollinson S, Pickering-Brown S, Snowden JS, et al. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2014;40(6):686&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117616</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee VM-Y, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One. 2012;7(6):e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135(Pt 3):751&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas AM, Sarlls JE, Kwan JY, Bageac D, Gala ZS, Danielian LE, et al. Pathology of callosal damage in ALS: An ex-vivo, 7 T diffusion tensor MRI study. Neuroimage Clin. 2017;15:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429246</ArticleId><ArticleId IdType="pubmed">28529876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, O&#x2019;brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler. 2006;7(2):67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Li W, Li L, Wang N, Li X, Gao M, et al. Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. Neuroscience. 2012;10(201):297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">22116052</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisafulli SG, Brajkovic S, Cipolat Mis MS, Parente V, Corti S. Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2018;55(4):2789&#x2013;2813.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455693</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, Deigendesch N, M&#xfc;ller K, Weishaupt JH, Krannich A, R&#xf6;hle R, et al. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis&#x2013;A Pilot Study. PLoS One. 2015;10(10):e0139684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596620</ArticleId><ArticleId IdType="pubmed">26444282</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559(7713):269&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">29973723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier O, Gitler AD. Neurodegenerative gene&#x2019;s function is not all about those bases. Nature. 2020;585(7823):34&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">32814910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan C. Drug developers switch gears to inhibit STING. Nat Biotechnol. 2019;37(3):199&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">30833772</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>